Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...
Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...
NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical ...
Pfizer (NYSE:PFE) announced its intention to sell its entire residual shareholding in Haleon plc, reflecting a divestment ...
The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) in adults with oestrogen receptor (ER)-positive, human epidermal growth ...
Arvinas, Inc. (NASDAQ ... The company’s lead program, vepdegestrant (vepdeg), is being developed with Pfizer as a potential best-in-class ER-targeting backbone therapy for breast cancer treatment.
TAMPA, Fla. (Mar. 18, 2025) — Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets ...
In addition to the VERITAC-2 trial, Arvinas has been exploring the potential of vepdegestrant in combination therapies. The company has shown promising results when combining vepdegestrant with Pfizer ...
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback